The tweet was deleted by the author.
But we saved everything 🙂.
NeuroPace Inc has released the results of its three year post approval study on the RNS System, now published in Neurology.
The findings suggest that the RNS System is driving a shift in the standard of care for patients, highlighting substantial improvements in life altering outcomes and confident care delivery. NeuroPace Inc expects these data to inform clinicians and support broader adoption of its neurostimulation technology. Additional safety information and access to the publication are provided directly by the company.
NeuroPace previously released NAUTILUS Study results on neuromodulation for drug-resistant idiopathic generalized epilepsy at the 2026 AAN Annual Meeting, according to company disclosures. The company reported advances in this area of treatment in data highlighted at the conference. Detailed findings from the NAUTILUS Study were also presented in a separate release.